Navacaprant is an highly selective kappa opioid receptor antagonist expected to modulate reward processing pathways and mediate depressive states.

The approval of Opdivo Qvantig was supported by data from the randomized, open-label phase 3 CheckMate-67T study.

The Company has been granted Competitive Generic Therapy designation, which allows for 180 days of marketing exclusivity.

The phase 3 STEER study enrolled 127 treatment-naïve patients aged 2 to less than 18 years with SMA type 2 who were able to sit but had never walked independently.

Between 1999 and 2022, there were 63,550,429 deaths in the US, of which 0.06% had cold recorded as an underlying or contributing cause of death. (HealthDay News) — From 1999 to 2022, there was ...

Compared with 2022, in 2023, state and local governments accounted for a higher share of spending. (HealthDay News) — Health care spending in the United States reached $4.9 trillion and ...

(HealthDay News) — For adults with migraine, atogepant 60mg once daily was superior to placebo for efficacy and functional measures of treatment across 3 trials, according to research published online ...

The approval was based on data from the randomized, placebo-controlled, double-blind, phase 3 RATIONALE-305 trial.

According to Vertex Pharmaceuticals, approximately 300 additional people with CF are now eligible to receive treatment.